News | June 10, 2026
GSK bets big on oncology with $10.6 billion Nuvalent acquisition
Deal brings late-stage lung cancer candidates zidesamtinib and neladalkib into GSK’s portfolio
Deal brings late-stage lung cancer candidates zidesamtinib and neladalkib into GSK’s portfolio
Exclusive Asia-Pacific licensing agreement for Bejescin strengthens the company’s nephrology and autoimmune disease portfolio
Investigational once-weekly GLP-1 and amylin receptor agonist achieves up to 14.6% weight loss and significant blood sugar reductions
The agreement underscores Roche’s commitment to advancing innovative therapies for blood cancers and other serious diseases
An exploratory overall survival signal also leaned in favor of the combination, though the companies noted the result remains preliminary
Anti-GD2 monoclonal antibody for high-risk neuroblastoma advances toward BLA submission following successful tech transfer from California to Bengaluru
This alliance, covering up to 12 antibody drugs, highlights the growing trend of large-scale collaborations between Chinese biotech firms and global pharmaceutical giants
Proprietary technologies in LNP-based delivery of mRNA and DNA vectors to advance T-CURX innovative in vivo CAR-T assets into clinical trials one year earlier
The designation marks the first Breakthrough Therapy recognition for calderasib and is backed by positive results from the Phase 1 KANDLELIT-001 clinical trial
The decision now moves to the European Commission, with a final ruling expected by the third quarter of 2026
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
